A Phase II, double-blind, placebo-controlled, ascending-dose study of eritoran (E5564), a lipid a antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass

Elliott Bennett-Guerrero*, Hilary P. Grocott, Jerrold H. Levy, Kevin A. Stierer, Charles W. Hogue, Albert T. Cheung, Mark F. Newman, Alison A. Carter, Daniel P. Rossignol, Charles D. Collard

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

53 Scopus citations

Fingerprint

Dive into the research topics of 'A Phase II, double-blind, placebo-controlled, ascending-dose study of eritoran (E5564), a lipid a antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass'. Together they form a unique fingerprint.

Medicine & Life Sciences